Showing results (1551-1560 of 1,619) with videos related to
Sort By:
Pageof 162
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.Cancer|September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialDarren R Feldman, Yasser Ged, Chung-Han Lee, et al.Urologic Oncology|April 15, 2017
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomyDaniel M Tennenbaum, Brandon J Manley, Emily Zabor, et al.Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.European Urology|February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing NephrectomyMaria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Genome-wide association studies of Down syndrome associated congenital heart defectsElizabeth R Feldman, Yunqi Li, David J Cutler, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumorsR S Matulewicz, F Baky, N Liso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer GroupDarren R Feldman, Anja Lorch, Andrew Kramar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.Pageof 162